JP2000512652A5 - - Google Patents

Download PDF

Info

Publication number
JP2000512652A5
JP2000512652A5 JP1998502317A JP50231798A JP2000512652A5 JP 2000512652 A5 JP2000512652 A5 JP 2000512652A5 JP 1998502317 A JP1998502317 A JP 1998502317A JP 50231798 A JP50231798 A JP 50231798A JP 2000512652 A5 JP2000512652 A5 JP 2000512652A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP1998502317A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000512652A (ja
Filing date
Publication date
Priority claimed from DE19624668A external-priority patent/DE19624668A1/de
Application filed filed Critical
Publication of JP2000512652A publication Critical patent/JP2000512652A/ja
Publication of JP2000512652A5 publication Critical patent/JP2000512652A5/ja
Withdrawn legal-status Critical Current

Links

JP10502317A 1996-06-20 1997-06-20 腫瘍の治療または免疫抑制におけるピリジルアルカン、ピリジルアルケンおよび/またはピリジルアルキン酸アミド類の用途 Withdrawn JP2000512652A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19624668A DE19624668A1 (de) 1996-06-20 1996-06-20 Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
DE19624668.7 1996-06-20
PCT/EP1997/003244 WO1997048397A1 (en) 1996-06-20 1997-06-20 Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression

Publications (2)

Publication Number Publication Date
JP2000512652A JP2000512652A (ja) 2000-09-26
JP2000512652A5 true JP2000512652A5 (2) 2005-02-10

Family

ID=7797502

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10502317A Withdrawn JP2000512652A (ja) 1996-06-20 1997-06-20 腫瘍の治療または免疫抑制におけるピリジルアルカン、ピリジルアルケンおよび/またはピリジルアルキン酸アミド類の用途

Country Status (10)

Country Link
EP (1) EP0912176B1 (2)
JP (1) JP2000512652A (2)
AT (1) ATE224713T1 (2)
AU (1) AU3262497A (2)
DE (2) DE19624668A1 (2)
DK (1) DK0912176T3 (2)
ES (1) ES2181006T3 (2)
PT (1) PT912176E (2)
WO (1) WO1997048397A1 (2)
ZA (1) ZA975443B (2)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451816B1 (en) 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
JPH10338658A (ja) * 1997-04-08 1998-12-22 Hoechst Marion Roussel Kk レチノイド作用調節剤
US6903118B1 (en) 1997-12-17 2005-06-07 Klinge Pharma Gmbh Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
DE19756235A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
DE19756212A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
DE19756261A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
DE19818044A1 (de) * 1998-04-22 1999-10-28 Klinge Co Chem Pharm Fab Verwendung von Vitamin-PP-Verbindungen
WO2000009132A1 (en) * 1998-08-12 2000-02-24 Smithkline Beecham Corporation Calcilytic compounds
DE19908483A1 (de) * 1999-02-26 2000-10-05 Klinge Co Chem Pharm Fab Inhibitoren der zellulären Niacinamidmononucleotid-Bildung
EP1031564A1 (en) * 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
JP2004507465A (ja) * 2000-08-11 2004-03-11 ワイス エストロゲン受容体陽性癌腫の治療方法
IL155093A0 (en) 2000-09-29 2003-10-31 Glaxo Group Ltd Morpholin-acetamide derivatives for the treatment on inflammatory diseases
EP1348434A1 (en) * 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
GB0207445D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
JP4521463B2 (ja) * 2005-03-17 2010-08-11 ファイザー株式会社 疼痛の治療に有用なn−(n−スルホニルアミノメチル)シクロプロパンカルボキサミド誘導体
PE20071159A1 (es) 2005-10-31 2007-11-30 Schering Corp Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina
WO2007053498A1 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
WO2007053499A2 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
HUP0600809A3 (en) * 2006-10-27 2008-09-29 Richter Gedeon Nyrt New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
EP2098231A1 (en) 2008-03-05 2009-09-09 Topotarget Switzerland SA Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
RU2529468C2 (ru) 2008-06-24 2014-09-27 Топотаргет А/С Производные 1, 2-дигидроциклобутендиона в качестве ингибиторов фосфорибозилтрансферазы никотинамида
JP5688367B2 (ja) 2008-08-29 2015-03-25 トポターゲット・アクティーゼルスカブTopoTarget A/S 新規なウレアおよびチオウレア誘導体
CA2768338A1 (en) 2009-07-17 2011-01-20 Topotarget A/S Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
WO2011121055A1 (en) 2010-03-31 2011-10-06 Topotarget A/S Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
JP6038792B2 (ja) 2010-09-03 2016-12-07 フォーマ ティーエム, エルエルシー. 癌などの疾患の治療のためのnampt阻害剤としての4−{[(ピリジン−3−イル−メチル)アミノカルボニル]アミノ}ベンゼン−スルホン誘導体
CN106243023A (zh) 2010-09-03 2016-12-21 福马Tm有限责任公司 用于抑制nampt的胍化合物和组合物
PE20140011A1 (es) 2010-09-03 2014-01-31 Forma Tm Llc Compuestos y composiciones novedosos para la inhibicion de nampt
KR101916481B1 (ko) * 2010-09-29 2018-11-07 인터벳 인터내셔널 비.브이. N-헤테로아릴 화합물
AU2011329233A1 (en) 2010-11-15 2013-05-23 Abbvie Deutschland Gmbh & Co Kg NAMPT and ROCK inhibitors
EP2640704A1 (en) 2010-11-15 2013-09-25 Abbvie Inc. Nampt inhibitors
RU2017112522A (ru) 2011-05-04 2019-01-24 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
WO2012154194A1 (en) 2011-05-09 2012-11-15 Forma Tm, Llc Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)
US8975398B2 (en) 2012-05-11 2015-03-10 Abbvie Inc. NAMPT inhibitors
AR091022A1 (es) 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
MX2014013758A (es) 2012-05-11 2015-02-05 Abbvie Inc Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
CA2873075A1 (en) 2012-05-11 2013-07-14 Abbvie Inc. Nampt inhibitors
WO2014085607A1 (en) 2012-11-29 2014-06-05 Karyopharm Therapeutics Inc. Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
EP3016946B1 (en) 2013-07-03 2022-10-12 Karyopharm Therapeutics Inc. Substituted benzofuranyl and benzoxazolyl compounds and pharmaceutical uses thereof
WO2015042414A1 (en) 2013-09-20 2015-03-26 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same
HK1255438A1 (zh) 2015-08-18 2019-08-16 卡尔约药物治疗公司 用於治疗癌症的(s,e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺
WO2017117447A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof
TWI835714B (zh) 2016-10-18 2024-03-21 美商思進公司 菸鹼醯胺腺嘌呤二核苷酸補救合成(salvage pathway)抑制劑之靶向投遞
WO2018086703A1 (en) 2016-11-11 2018-05-17 Bayer Pharma Aktiengesellschaft Dihydropyridazinones substituted with phenylureas
WO2018201087A1 (en) 2017-04-27 2018-11-01 Seattle Genetics, Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
JP2021512103A (ja) 2018-01-31 2021-05-13 バイエル アクチェンゲゼルシャフトBayer Aktiengesellschaft Nampt阻害剤を含む抗体薬物複合体(adcs)
KR102831570B1 (ko) 2018-05-04 2025-07-10 레미디 플랜, 인크. 암 줄기 세포를 표적화하는 암 치료
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
AU2020378067A1 (en) 2019-11-06 2022-05-26 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
JP2024518089A (ja) 2021-05-13 2024-04-24 リメディー プラン,インコーポレーテッド Nampt阻害剤とその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778796A (en) * 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
JP2832979B2 (ja) * 1988-02-15 1998-12-09 武田薬品工業株式会社 不飽和カルボン酸アミド誘導体
EP0343307A1 (en) * 1988-05-26 1989-11-29 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. 4-Piperidinealkanamine derivatives
US5352684A (en) * 1990-04-10 1994-10-04 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyridines as medicaments
WO1991015485A1 (de) * 1990-04-10 1991-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue pyridinester

Similar Documents

Publication Publication Date Title
JP2000517343A5 (2)
JP2001504701A5 (2)
JP2000502280A5 (2)
JP2000501771A5 (2)
JP2000501599A5 (2)
JP2000501018A5 (2)
JP2000501324A5 (2)
JP2001502986A5 (2)
JP2000502472A5 (2)
JP2000501825A5 (2)
JP2000501338A5 (2)
JP2000500874A5 (2)
JP2000512652A5 (2)
JP2000502425A5 (2)
JP2000502485A5 (2)
JP2000502568A5 (2)
JP2000501774A5 (2)
JP2000500912A5 (2)
JP2000502570A5 (2)
JP2000514155A5 (2)
JP2000501876A5 (2)
JP2000501744A5 (2)
JP2000511953A5 (2)
JP2000501229A5 (2)
JP2000502316A5 (2)